ARVN News and Press, Arvinas Inc. From 06/17/20

NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside...

NEW HAVEN, Conn., June 11, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Linda Bain has joined its Board of Directors. Ms. Bain, who is currently the Chi...

NEW HAVEN, Conn., June 05, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, will participate in a fireside chat ...

 Gainers:  Sonoma Pharmaceuticals (NASDAQ: SNOA ) +145% . More news on: Sonoma Pharmaceuticals, Inc., Adaptimmune Therapeutics plc, Phio Pharmaceuticals Corp., Stocks on the move, , Read more ...

Arvinas's ( ARVN -28.6% ) updated data from the dose escalation portion of Phase 1/2 trial of ARV-110 in metastatic castration-resistant prostate cancer (mCRPC) patients showed that the treatment was generally well-tolerated. More news on: Arvinas, Inc., Healthcare stocks news, ...

ARCA biopharma (NASDAQ: ABIO )  -28% . More news on: ARCA biopharma, Inc., ToughBuilt Industries, Inc., Canopy Growth Corporation, Stocks on the move, , Read more ...

- Clear efficacy signal with two ongoing confirmed PSA responses, including one associated with a confirmed RECIST response - - Data represent the first demonstration of PROTAC ® -mediated degradation of a disease-causing protein in humans - NEW HAVEN, Conn., May 29, 2020 (GLOB...

Rational for a Copycat Strategy Research from Barclay and Novus published in October 2019 found that a stock selection copycat strategy that combines conviction and consensus of fund managers that have longer-term views outperformed the S&P 500 by 3.80% on average annually from Q1 2004...

Investing in companies with superior growth rates can produce outstanding returns over the long term. A stock is essentially a share in the ownership of a business, and the price of the stock will follow the value of the business over time. When the business is growing rapidly and ideally ac...

NEW HAVEN, Conn., May 20, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that its 2020 Annual Meeting of Stockholders, to be held on Wednesday, June 3, 2020 at...